The burgeoning popularity of retatrutide, initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Availability these medications remains a complex landscape, with National Health Service coverage currently limited and specialist practices offering prescriptions at a substantial price. C